Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| WD 40 COWDFC · Entity 4262 | Director | February 05, 2026 | February 06, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
WD 40 CO
Report date February 05, 2026 · Filed February 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 6,898 |
Reported balance
After 2026-02-05 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-02-05 · Purchase · Acquired 424 · Balance 6,898 F1: Represents: (i) 1,275 shares acquired via stock purchases by Reporting Owner, and (ii) 5,623 vested RSUs treated as common stock equivalents. Following termination of Reporting Person's service as a director, vested RSUs will be settled with Issuer's common stock. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents: (i) 1,275 shares acquired via stock purchases by Reporting Owner, and (ii) 5,623 vested RSUs treated as common stock equivalents. Following termination of Reporting Person's service as a director, vested RSUs will be settled with Issuer's common stock.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
RESMED INC
Report date June 30, 2023 · Filed June 30, 2023
Section 16 reporting ended · disclosed 2023-06-30. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| ResMed Common StockSEC Table I · non-derivative | Direct | 89,729 |
Reported balance
Holding disclosure · report date 2023-06-30 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 89,729 |
SEQUENOM INC
Report date September 07, 2016 · Filed September 07, 2016
Section 16 reporting ended · disclosed 2016-09-07. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2016-09-07 transaction · row 1
1 source rowRow 1 · 2016-09-07 · Other · Disposed 112,969 · Balance 0 F1: Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated July 26, 2016, among the Issuer, Laboratory Corporation of America Holdings, a Delaware corporation ("Parent"), and Savoy Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser") in exchange for a cash consideration of $2.40 per share, without interest, subject to any required withholding of taxes. Pursuant to the Merger Agreement, the Purchaser merged with and into the Issuer, with the Issuer surviving as a wholly-owned subsidiary of Parent (the "Merger"). |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.11 · Expires 2026-06-14 | Direct | 0 |
Reported balance
After 2016-09-07 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2016-09-07 · Disposition to issuer · Disposed 20,000 · Balance 0 F2: This option was cancelled in the Merger in exchange for a cash payment equal to $2.40 per share (without interest) minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated July 26, 2016, among the Issuer, Laboratory Corporation of America Holdings, a Delaware corporation ("Parent"), and Savoy Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser") in exchange for a cash consideration of $2.40 per share, without interest, subject to any required withholding of taxes. Pursuant to the Merger Agreement, the Purchaser merged with and into the Issuer, with the Issuer surviving as a wholly-owned subsidiary of Parent (the "Merger").
F2: This option was cancelled in the Merger in exchange for a cash payment equal to $2.40 per share (without interest) minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 05, 2026 Filed Feb 6, 2026 23:11 UTC | WD 40 CO WDFC · Entity 4262 | PurchaseCommon Stock | 424 | $247.15 | $104,791.60 |
DisclosureSEC source: 0000105132-26-000011 · form4.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,898 F1 · balance_after: Represents: (i) 1,275 shares acquired via stock purchases by Reporting Owner, and (ii) 5,623 vested RSUs treated as common stock equivalents. Following termination of Reporting Person's service as a director, vested RSUs will be settled with Issuer's common stock. Read SEC document |
| December 12, 2025 Filed Dec 13, 2025 01:09 UTC | WD 40 CO WDFC · Entity 4262 | GrantCommon Stock | 612 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000105132-25-000123 · form4.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,474 F1 · shares: Represents a restricted stock unit ("RSU") award covering shares of Issuer's common stock granted in accordance with Issuer's Directors' Compensation Policy and Election Plan adopted on June 16, 2025. This RSU award, which was granted effective December 12, 2025 and had an aggregate fair market value of approximately $125,000 on such date, is the non-elective portion of annual director compensation and vests upon grant. F1 · price: Represents a restricted stock unit ("RSU") award covering shares of Issuer's common stock granted in accordance with Issuer's Directors' Compensation Policy and Election Plan adopted on June 16, 2025. This RSU award, which was granted effective December 12, 2025 and had an aggregate fair market value of approximately $125,000 on such date, is the non-elective portion of annual director compensation and vests upon grant. F2 · balance_after: Represents: (i) 851 shares acquired via stock purchases by Reporting Owner, and (ii) 5,623 vested RSUs treated as common stock equivalents. Following termination of Reporting Person's service as a director, vested RSUs will be settled with Issuer's common stock. Read SEC document |
| October 30, 2025 Filed Oct 30, 2025 20:55 UTC | WD 40 CO WDFC · Entity 4262 | PurchaseCommon Stock | 523 | $196.37 | $102,701.51 |
DisclosureSEC source: 0000105132-25-000093 · form4.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,862 F1 · balance_after: Represents: (i) 851 shares acquired via stock purchases by Reporting Owner, and (ii) 5,011 vested RSUs (previously reported as 5,018 in error) treated as common stock equivalents. Following termination of Reporting Person's service as a director, vested RSUs will be settled with Issuer's common stock. Read SEC document |
| December 12, 2024 Filed Dec 16, 2024 21:17 UTC | WD 40 CO WDFC · Entity 4262 | GrantCommon Stock | 412 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000105132-24-000111 · form4.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,346 F1 · shares: Represents a restricted stock unit ("RSU") award covering shares of Issuer's common stock granted in accordance with Issuer's Directors' Compensation Policy and Election Plan adopted on October 3, 2024. This RSU award, which was granted effective December 12, 2024 and had an aggregate fair market value of approximately $110,000 on such date, is the non-elective portion of annual director compensation and vests upon grant. F1 · price: Represents a restricted stock unit ("RSU") award covering shares of Issuer's common stock granted in accordance with Issuer's Directors' Compensation Policy and Election Plan adopted on October 3, 2024. This RSU award, which was granted effective December 12, 2024 and had an aggregate fair market value of approximately $110,000 on such date, is the non-elective portion of annual director compensation and vests upon grant. F2 · balance_after: Represents: (i) 328 shares acquired via stock purchases by Reporting Owner, and (ii) 5,018 vested RSUs treated as common stock equivalents. Following termination of Reporting Person's service as a director, vested RSUs will be settled with Issuer's common stock. Read SEC document |
| April 12, 2024 Filed Apr 12, 2024 20:17 UTC | WD 40 CO WDFC · Entity 4262 | PurchaseCommon Stock | 328 | $234.75 | $76,998.00 |
DisclosureSEC source: 0000105132-24-000027 · form4.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,934 F1 · balance_after: Represents: (i) 328 shares acquired via stock purchases by Reporting Owner, and (ii) 4,606 vested RSUs treated as common stock equivalents. Following termination of the Reporting Person's service as a director, vested RSUs will be settled with Issuer's common stock. Read SEC document |
| December 12, 2023 Filed Dec 13, 2023 14:26 UTC | WD 40 CO WDFC · Entity 4262 | GrantCommon Stock | 406 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000105132-23-000103 · form4.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,606 F1 · security: Represents fully vested RSUs treated as common stock equivalents. Following termination of the Reporting Person's service as a director, the RSUs will be settled with Issuer's common stock. F2 · shares: Represents a restricted stock unit ("RSU") award covering shares of Issuer's common stock granted in accordance with the Issuer's Directors' Compensation Policy and Election Plan adopted on October 5, 2023. This RSU award, which was granted effective December 12, 2023 and had an aggregate fair market value of approximately $97,000 on such date, is the non-elective portion of annual director compensation and vests upon grant. F2 · price: Represents a restricted stock unit ("RSU") award covering shares of Issuer's common stock granted in accordance with the Issuer's Directors' Compensation Policy and Election Plan adopted on October 5, 2023. This RSU award, which was granted effective December 12, 2023 and had an aggregate fair market value of approximately $97,000 on such date, is the non-elective portion of annual director compensation and vests upon grant. F1 · balance_after: Represents fully vested RSUs treated as common stock equivalents. Following termination of the Reporting Person's service as a director, the RSUs will be settled with Issuer's common stock. Read SEC document |
| June 05, 2023 Filed Jun 7, 2023 16:20 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 1,500 | $219.79 | $329,685.00 |
DisclosureSEC source: 0001127602-23-018089 · form4.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 89,729 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted November 29, 2022. F2 · balance_after: Includes 56.7807 shares of ResMed stock purchased on April 28, 2023, through the ResMed Employee Stock Purchase Plan. Read SEC document |
| May 03, 2023 Filed May 4, 2023 23:49 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 1,500 | $237.64 | $356,460.00 |
DisclosureSEC source: 0001127602-23-014596 · form4.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 91,172 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted November 29, 2022. Read SEC document |
| April 03, 2023 Filed Apr 5, 2023 19:28 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 1,500 | $218.23 | $327,345.00 |
DisclosureSEC source: 0001127602-23-012530 · form4.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 92,672 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted November 29, 2022. Read SEC document |
| March 03, 2023 Filed Mar 7, 2023 17:32 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 1,500 | $216.69 | $325,035.00 |
DisclosureSEC source: 0001127602-23-009228 · form4.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,172 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted November 29, 2022. Read SEC document |
| February 03, 2023 Filed Feb 6, 2023 18:55 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 1,500 | $224.50 | $336,750.00 |
DisclosureSEC source: 0001127602-23-003509 · form4.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,672 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 17:54 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 1,500 | $210.07 | $315,105.00 |
DisclosureSEC source: 0001127602-23-000789 · form4.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,172 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| December 13, 2022 Filed Dec 15, 2022 21:09 UTC | WD 40 CO WDFC · Entity 4262 | GrantCommon Stock | 840 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-22-021646 · doc1.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,200 F1 · security: Represents fully vested RSUs treated as common stock equivalents. Following termination of the Reporting Person's service as a director, the RSUs will be settled with Issuer's common stock. F2 · shares: Represents an elective and a non-elective restricted stock unit ("RSU") award covering shares of Issuer's common stock granted in accordance with the Issuer's Directors' Compensation Policy and Election Plan adopted on October 12, 2021. This RSU award, which was effective December 13, 2022, had an aggregate fair market value of approximately $140,000 on such date, and vests immediately. The award was composed of 360 elective RSUs (representing approximately $60,000 of annual base compensation for directors) and 480 non-elective RSUs (representing approximately $80,000 of annual director compensation). F2 · price: Represents an elective and a non-elective restricted stock unit ("RSU") award covering shares of Issuer's common stock granted in accordance with the Issuer's Directors' Compensation Policy and Election Plan adopted on October 12, 2021. This RSU award, which was effective December 13, 2022, had an aggregate fair market value of approximately $140,000 on such date, and vests immediately. The award was composed of 360 elective RSUs (representing approximately $60,000 of annual base compensation for directors) and 480 non-elective RSUs (representing approximately $80,000 of annual director compensation). F1 · balance_after: Represents fully vested RSUs treated as common stock equivalents. Following termination of the Reporting Person's service as a director, the RSUs will be settled with Issuer's common stock. Read SEC document |
| December 05, 2022 Filed Dec 6, 2022 20:07 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 1,500 | $229.81 | $344,715.00 |
DisclosureSEC source: 0001127602-22-026963 · form4.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,672 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| November 28, 2022 Filed Nov 29, 2022 18:58 UTC | RESMED INC RMD · Entity 2692 | GiftResMed Common Stock | 7,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-026463 · form4.xml · nonDerivative · entry 2 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,172 F1 · kind: Gift of shares to The San Diego Foundation, a 501(c)(3) nonprofit organization. Mr. Pendarvis has no beneficial interest, control or dispositive power over the gifted shares. Read SEC document |
| November 25, 2022 Filed Nov 29, 2022 18:58 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock Options · Derivative | 683 | $0.00 Strike: $146.34 | $0.00 |
DisclosureSEC source: 0001127602-22-026463 · form4.xml · derivative · entry 3 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,540 Underlying: ResMed Common Stock · 683 shares Expires 2026-11-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| November 25, 2022 Filed Nov 29, 2022 18:58 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock | 683 | $146.34 | $99,950.22 |
DisclosureSEC source: 0001127602-22-026463 · form4.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,472 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 23, 2022 Filed Nov 23, 2022 22:37 UTC | RESMED INC RMD · Entity 2692 | Tax withholdingResMed Common Stock | 6,911 | $224.40 | $1,550,828.40 |
DisclosureSEC source: 0001127602-22-026352 · form4.xml · nonDerivative · entry 2 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,789 F2 · kind: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 11/21/2019. Read SEC document |
| November 23, 2022 Filed Nov 23, 2022 22:37 UTC | RESMED INC RMD · Entity 2692 | GrantResMed Common Stock | 12,389 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-026352 · form4.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,700 F1 · kind: Represents performance-based restricted stock units granted on November 21, 2019. The shares were earned on November 23, 2022, when the compensation committee certified that the performance metrics were met. Read SEC document |
| November 11, 2022 Filed Nov 15, 2022 23:26 UTC | RESMED INC RMD · Entity 2692 | Tax withholdingResMed Common Stock | 279 | $225.18 | $62,825.22 |
DisclosureSEC source: 0001127602-22-025655 · form4.xml · nonDerivative · entry 3 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,311 F3 · kind: Disposition to issuer for tax withholding on scheduled vesting of Restricted Stock Units granted 11/18/2021. Read SEC document |
| November 11, 2022 Filed Nov 15, 2022 23:26 UTC | RESMED INC RMD · Entity 2692 | Tax withholdingResMed Common Stock | 337 | $225.18 | $75,885.66 |
DisclosureSEC source: 0001127602-22-025655 · form4.xml · nonDerivative · entry 2 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,590 F2 · kind: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 11/19/2020. Read SEC document |
| November 11, 2022 Filed Nov 15, 2022 23:26 UTC | RESMED INC RMD · Entity 2692 | Tax withholdingResMed Common Stock | 450 | $225.18 | $101,331.00 |
DisclosureSEC source: 0001127602-22-025655 · form4.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,927 F1 · kind: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 11/21/2019. Read SEC document |
| November 03, 2022 Filed Nov 4, 2022 15:34 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 1,545 | $215.23 | $332,530.35 |
DisclosureSEC source: 0001127602-22-024941 · form4.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,334 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 15:35 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 1,545 | $220.19 | $340,193.55 |
DisclosureSEC source: 0001127602-22-023624 · form4.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,879 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| September 06, 2022 Filed Sep 7, 2022 20:54 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 1,545 | $216.92 | $335,141.40 |
DisclosureSEC source: 0001127602-22-022156 · form4.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,424 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| August 18, 2022 Filed Aug 22, 2022 19:09 UTC | RESMED INC RMD · Entity 2692 | GrantResMed Common Stock | 1,683 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-021424 · form4.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,969 F1 · kind: Represents performance-based restricted stock units granted on November 18, 2021. The shares were earned on August 18, 2022, when the compensation committee certified that the performance metrics were met. Stock units vest 1/3 each year on the anniversary of the grant. Read SEC document |
| August 03, 2022 Filed Aug 4, 2022 21:24 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 1,545 | $240.72 | $371,912.40 |
DisclosureSEC source: 0001127602-22-020493 · form4.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,286 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| July 05, 2022 Filed Jul 6, 2022 22:31 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 1,545 | $212.33 | $328,049.85 |
DisclosureSEC source: 0001127602-22-019009 · form4.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,831 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| June 03, 2022 Filed Jun 7, 2022 12:35 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 1,545 | $209.44 | $323,584.80 |
DisclosureSEC source: 0001127602-22-016949 · form4.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,376 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · balance_after: Includes 62.7151 shares of ResMed stock purchased on April 29, 2022, through the ResMed Employee Stock Purchase Plan. Read SEC document |
| May 03, 2022 Filed May 4, 2022 21:03 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 1,545 | $200.00 | $309,000.00 |
DisclosureSEC source: 0001127602-22-013220 · form4.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,858 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| April 04, 2022 Filed Apr 5, 2022 20:33 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 1,544 | $246.60 | $380,750.40 |
DisclosureSEC source: 0001127602-22-011560 · form4.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,403 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| March 03, 2022 Filed Mar 4, 2022 19:04 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 1,544 | $250.62 | $386,957.28 |
DisclosureSEC source: 0001127602-22-008215 · form4.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,947 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| February 03, 2022 Filed Feb 5, 2022 00:14 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 1,544 | $232.87 | $359,551.28 |
DisclosureSEC source: 0001127602-22-003444 · form4.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administration Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,491 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| January 03, 2022 Filed Jan 4, 2022 23:12 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 1,544 | $258.52 | $399,154.88 |
DisclosureSEC source: 0001127602-22-000662 · form4.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administration Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,035 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| December 14, 2021 Filed Dec 16, 2021 01:07 UTC | WD 40 CO WDFC · Entity 4262 | GrantCommon Stock | 581 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-21-022125 · doc1.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,360 F1 · shares: Restricted Stock Units (Common Stock equivalents) were granted pursuant to the WD-40 Company 2016 Stock Incentive Plan for non-elective and elective portions of annual director compensation in accordance with the Issuer's Directors' Compensation Policy and Election Plan. The Restricted Stock Units will be settled solely with Issuer Common Stock upon termination of the reporting person's service as a director. F1 · price: Restricted Stock Units (Common Stock equivalents) were granted pursuant to the WD-40 Company 2016 Stock Incentive Plan for non-elective and elective portions of annual director compensation in accordance with the Issuer's Directors' Compensation Policy and Election Plan. The Restricted Stock Units will be settled solely with Issuer Common Stock upon termination of the reporting person's service as a director. F2 · balance_after: Total represents 3,360 Restricted Stock Units (Common Stock equivalents). Read SEC document |
| December 03, 2021 Filed Dec 6, 2021 21:57 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 1,544 | $257.93 | $398,243.92 |
DisclosureSEC source: 0001127602-21-030371 · form4.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,579 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| November 18, 2021 Filed Nov 18, 2021 21:04 UTC | RESMED INC RMD · Entity 2692 | GrantResMed Common Stock | 986 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-029539 · form4.xml · nonDerivative · entry 3 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,123 F3 · kind: Represents performance-based restricted stock units granted on November 19, 2020. The shares were earned on November 18, 2021, when the compensation committee certified that the performance metrics were met for this portion of the grant. The earned units remain subject to time-vesting requirements, and are scheduled to vest on the three-year anniversary of the grant, assuming continued service through the vesting date. Read SEC document |
| November 18, 2021 Filed Nov 23, 2021 01:00 UTC | RESMED INC RMD · Entity 2692 | GrantResMed Common Stock Options · Derivative | 5,931 | $0.00 Strike: $263.16 | $0.00 |
DisclosureSEC source: 0000943819-21-000039 · primary_doc.xml · derivative · entry 2 PENDARVIS DAVID · CIK 0001196723 · Chief Administration Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,931 Underlying: ResMed Common Stock · 5,931 shares Expires 2028-11-18 F1 · derivative.exercise_date: Represents date options first become exercisable. Options vest 1/3 annually each November 11, 2022, 2023 and 2024. Read SEC document |
| November 17, 2021 Filed Nov 18, 2021 21:04 UTC | RESMED INC RMD · Entity 2692 | Tax withholdingResMed Common Stock | 9,655 | $254.81 | $2,460,190.55 |
DisclosureSEC source: 0001127602-21-029539 · form4.xml · nonDerivative · entry 2 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,137 F2 · kind: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 11/14/2018. Read SEC document |
| November 16, 2021 Filed Nov 18, 2021 21:04 UTC | RESMED INC RMD · Entity 2692 | GrantResMed Common Stock | 17,307 | $254.81 | $4,409,996.67 |
DisclosureSEC source: 0001127602-21-029539 · form4.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,792 F1 · kind: Represents performance-based restricted stock units granted on November 14, 2018. The shares were earned on November 16, 2021, when the compensation committee certified that the performance metrics were met. Read SEC document |
| November 11, 2021 Filed Nov 15, 2021 19:06 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock Options · Derivative | 983 | $0.00 Strike: $101.64 | $0.00 |
DisclosureSEC source: 0001127602-21-029097 · form4.xml · derivative · entry 4 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,468 Underlying: ResMed Common Stock · 983 shares Expires 2025-11-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| November 11, 2021 Filed Nov 15, 2021 19:06 UTC | RESMED INC RMD · Entity 2692 | GiftResMed Common Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-029097 · form4.xml · nonDerivative · entry 3 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,485 F2 · kind: Gift of shares to The San Diego Foundation, a 501(c)(3) nonprofit organization. Mr. Pendarvis has no beneficial interest, control or dispositive power over the gifted shares. F3 · balance_after: Includes 64.3996 shares of ResMed stock purchased on October 29, 2021, through the ResMed Employee Stock Purchase Plan. Read SEC document |
| November 11, 2021 Filed Nov 15, 2021 19:06 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock | 983 | $101.64 | $99,912.12 |
DisclosureSEC source: 0001127602-21-029097 · form4.xml · nonDerivative · entry 2 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,485 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 11, 2021 Filed Nov 15, 2021 19:06 UTC | RESMED INC RMD · Entity 2692 | Tax withholdingResMed Common Stock | 1,549 | $259.47 | $401,919.03 |
DisclosureSEC source: 0001127602-21-029097 · form4.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,502 F1 · kind: Disposition to issuer for tax withholding on scheduled vesting of Restricted Stock Units granted 11/14/2018, 11/21/2019 and 11/19/2020. Read SEC document |
| November 03, 2021 Filed Nov 5, 2021 15:57 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 1,485 | $264.29 | $392,470.65 |
DisclosureSEC source: 0001127602-21-028432 · form4.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,987 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| October 04, 2021 Filed Oct 5, 2021 16:57 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 1,487 | $260.79 | $387,794.73 |
DisclosureSEC source: 0001127602-21-026630 · form4.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,472 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| September 03, 2021 Filed Sep 7, 2021 16:57 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 1,487 | $292.16 | $434,441.92 |
DisclosureSEC source: 0001127602-21-024939 · form4.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,959 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| August 19, 2021 Filed Aug 20, 2021 16:00 UTC | RESMED INC RMD · Entity 2692 | GrantResMed Common Stock | 2,033 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-024091 · form4.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,446 F1 · kind: Represents performance-based restricted stock units granted on November 19, 2020. The shares were earned on August 19, 2021, when the compensation committee certified that the performance metrics were met. Stock units vest 1/3 each year on the anniversary of the grant. Read SEC document |
| August 03, 2021 Filed Aug 4, 2021 17:26 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 1,487 | $269.38 | $400,568.06 |
DisclosureSEC source: 0001127602-21-023038 · form4.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,413 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| July 06, 2021 Filed Jul 7, 2021 19:46 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 1,487 | $247.12 | $367,467.44 |
DisclosureSEC source: 0001127602-21-021673 · form4.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,900 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.